
With a world-spanning health crisis behind it, and with its ambition of strengthening the health preparedness on the horizon, providing a better framework for the drug approval process in the EU is needed. This is the recommendation from one of the European Parliament's central committees, ENVI, for the EU's future pharmaceutical strategy.
In practice, ENVI – which is the EU Committee on the Environment, Public Health and Food Safety – proposes that the Commission considers "how already established tools like accelerated authorization, early dialogue, the Prime scheme and expanded guidance can be used to make medicine available to patients at a faster pace," reads the committee's proposal for the EU pharmaceutical strategy, which will be put to a vote next week.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app